Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;165(12):3779-3785.
doi: 10.1007/s00701-023-05815-z. Epub 2023 Oct 2.

Impact of tailored multimodal treatment for unruptured brain arteriovenous malformation: comparison with a randomized trial of unruptured brain arteriovenous malformations

Taichi Ikedo  1 , Etsuko Hattori Yamamoto  2 , Hisae Mori  2 , Akihiro Niwa  2 , Saya Ozaki  2 , Yuji Kushi  2 , Koji Shimonaga  2 , Eika Hamano  2 , Kiyofumi Yamada  2 , Hirotoshi Imamura  2 , Koji Iihara  2 , Hiroharu Kataoka  2
Affiliations
Review

Impact of tailored multimodal treatment for unruptured brain arteriovenous malformation: comparison with a randomized trial of unruptured brain arteriovenous malformations

Taichi Ikedo et al. Acta Neurochir (Wien). 2023 Dec.

Abstract

Purpose: The first randomized controlled study on unruptured brain arteriovenous malformations (bAVM), the ARUBA trial, demonstrate the superiority of medical management; however, it failed to completely rule out the efficacy of therapeutic interventions due to several limitations. This study aimed to examine the outcomes of multimodal interventional treatment for bAVM in terms of safety and efficacy.

Methods: We reviewed 226 consecutive patients with unruptured bAVM admitted to our institute between 2002 and 2022. Treatment methods were divided into medical management and therapeutic intervention, including microsurgery, stereotactic surgery, and endovascular intervention. First, the choice of therapeutic modalities was assessed in the pre-ARUBA (before February 2014) and post-ARUBA (after March 2014) eras. Second, the incidence of symptomatic stroke or death and functional prognosis with a modified Rankin scale (mRS) score of ≥2 at 5 years was compared between the medical management and therapeutic intervention.

Results: In the pre- and post-ARUBA groups, 73% and 84% of patients underwent therapeutic interventions, respectively (p = 0.053). The rate of symptomatic stroke or death was lower in patients who underwent interventional therapies than in those who underwent medical management (9.7% vs. 22%, p = 0.022); however, the opposite was observed in the ARUBA trial (31% vs. 10%). The annual incidence of stroke or death was also lower in the interventional therapy group (4.3%/y vs. 1.8%/year, hazard ratio = 0.45, 95% confidence interval: 0.18-1.08, p = 0.032). The rate of mRS score of ≥2 after a 5-year follow-up was 18% and 6% in the medical treatment and intervention groups (p = 0.14).

Conclusions: The therapeutic intervention rate did not decrease, even after the publication of the ARUBA trial. The rate of stroke or death was lower in the intervention group, indicating that a tailored choice of multimodality is safe and effective for managing unruptured bAVM.

Keywords: ARUBA; Brain arteriovenous malformation; Multimodal treatment.

PubMed Disclaimer

References

    1. Cenzato M, Boccardi E, Beghi E, Vajkoczy P, Szikora I, Motti E, Regli L, Raabe A, Eliava S, Gruber A, Meling TR, Niemela M, Pasqualin A, Golanov A, Karlsson B, Kemeny A, Liscak R, Lippitz B, Radatz M et al (2017) European consensus conference on unruptured brain AVMs treatment (Supported by EANS, ESMINT, EGKS, and SINCH). Acta Neurochir 159:1059–1064. https://doi.org/10.1007/s00701-017-3154-8 - DOI - PubMed
    1. Grasso G (2014) The ARUBA study: what is the evidence? World Neurosurg 82:e576. https://doi.org/10.1016/j.wneu.2014.04.057 - DOI - PubMed
    1. Ilyas A, Chen CJ, Abecassis IJ, Al-Saiegh F, Ironside N, Jabbour PM, Tjoumakaris S, Gooch MR, Lee CC, Sheehan JP, Ding D (2022) Stereotactic radiosurgery for a randomized trial of unruptured brain arteriovenous malformations-eligible patients: a meta-analysis. Neurosurgery 91:684–692. https://doi.org/10.1227/neu.0000000000002115 - DOI - PubMed
    1. Izumo T, Okamura K, Takahira R, Matsunaga Y, Sadakata E, Maeda H, Yamaguchi S, Baba S, Morofuji Y, Hiu T, Horie N, Anda T, Kitagawa N, Tokunaga Y, Hayashi K, Matsumoto Y, Nagata I, Matsuo T (2022) Impact of pre-operative embolization with onyx for brain arteriovenous malformation surgery. Front Neurol 13:875260. https://doi.org/10.3389/fneur.2022.875260 - DOI - PubMed - PMC
    1. Javadpour M, Al-Mahfoudh R, Mitchell PS, Kirollos R (2016) Outcome of microsurgical excision of unruptured brain arteriovenous malformations in ARUBA-eligible patients. Br J Neurosurg 30:619–622. https://doi.org/10.1080/02688697.2016.1181153 - DOI - PubMed

LinkOut - more resources